MedPath

Topical Application of Latanoprost in Diabetic Retinopathy

Phase 4
Completed
Conditions
Diabetic Retinopathy
Interventions
Registration Number
NCT01225653
Lead Sponsor
University of Aarhus
Brief Summary

Randomized double-blinded two-year intervention study with topical application of latanoprost or placebo eye drops in patients with diabetic retinopathy.

Detailed Description

The primary objective is to study if a sustained contraction of pathologically dilated retinal arterioles can be obtained. Retinal arteriolar diameter and the diameter response to increased blood pressure is studied using the Dynamic Vessel Analyzer (Imedos, Germany.

The secondary objective is to study whether the intervention can halt the development of diabetic retinopathy, which is assessed by optical coherence tomography (OCT) scanning and fundus photography.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
27
Inclusion Criteria
  • Age 20-36 years old
  • Diabetes mellitus with retinopathy
Exclusion Criteria
  • Pregnancy
  • Previous ocular disease other than diabetic retinopathy
  • General disease with possible influence on the eye

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
LatanoprostLatanoprostTopical treatment with latanoprost
PlaceboLatanoprostPlacebo arm
Primary Outcome Measures
NameTimeMethod
The diameter of retinal arterioles24 months

The diameter of retinal arterioles will be assessed using the Dynamic Vessel Analyzer

Secondary Outcome Measures
NameTimeMethod
The severity of diabetic retinopathy24 months

Severity of diabetic retinopathy will be measured by optical coherence tomography (OCT) scanning and fundus photography

Trial Locations

Locations (1)

Department of Ophthalmology, Århus University Hospital

🇩🇰

Århus, Denmark

© Copyright 2025. All Rights Reserved by MedPath